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ABSTRACT
Efficient adjuvants have the potential to trigger both innate and adaptive immune responses
simultaneously. Flagellin is a unique pathogen-derived protein, which is recognized by pattern
recognition receptors  (PRRs) as well  as by B-cell  and T cell  receptors  thus providing an
important link between innate and adaptive immunity. The aforementioned properties define
flagellin  as  an  optimal  adjuvant.  The  induction  of  immunogenic  cell  death  could  be  an
additional  expectation  for  adjuvants  in  the  context  of  cancer  immunotherapy due to  their
ability to activate dendritic cells (DC) to present tumor antigens through the engulfment of
dying cells. The immunostimulatory potential of flagellin in the course of DC and lymphocyte
activation is well documented, however the exact mechanism is not fully explored. Based on
this limitation we sought to investigate the potential modulatory effects of flagellin on various
cell death processes knowing that it plays detrimental roles in regulating the final outcome of
various types of immune responses. 
Here we provide evidence that the pre-treatment of Jurkat T-cells with recombinant flagellin
is able to increase the degree of cell death provoked by FasL or TNF-α, and concomitantly
increases the cytotoxic potential of phytohemagglutinin activated T-lymphocytes in a TLR5
dependent way. In contrast to these flagellin-mediated effects on the death receptor-induced
signaling events, the mitochondrial apoptotic pathway remained unaffected. Furthermore, the
cell culture supernatant of wild type  Salmonella enteritidis bacteria,  but not their flagellin
deficient  variant,  was  able  to  enhance  the  Fas-induced  cell  death  process.  To  define  the
molecular  mechanisms of flagellin-mediated elevated levels of cell  death we were able to
detect the upregulation of RIP1-dependent signaling events. These findings demonstrate that
the cooperative actions of pattern recognition and different death receptors are able to initiate
the cell  death process with the mobilization  of RIP-dependent  cell  death modalities.  This
finding highlights the capability of flagellin to act as a potential adjuvant which is relevant for
tumor immunotherapy. 
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1. INTRODUCTION
The  immunogenicity  of  tumors  is  much  lower  than  the  intensity  of  adaptive  immune
responses induced by various infections. To circumvent this limitation, the expectation would
be to develop potent immune stimulatory strategies, which are able to increase the efficacy of
anti-tumor immunotherapies.  Efficient  activation of pattern recognition receptors (PRR) is
mandatory for DC maturation, migration to secondary lymphatic organs and potent antigen
presentation. Furthermore, the efficient engulfment of dead cells by DCs is essential for the
activation of naïve cytotoxic T cells to support all of these functional activities . Based on this
scenario a competent adjuvant must have the potential to activate innate immunity in concert
with the concomitant triggering of DC-mediated cross-presentation. 
It is well  established that the innate immune system can effectively be stimulated via the
recognition  of  microbe  associated  molecular  structures  referred  to  as  pathogen associated
molecular  patterns  (PAMPs)  which  are  not  expressed  by eukaryotic  hosts.  Flagellin  is  a
subunit  of bacterial  flagella,  which is  considered as a PAMP and recognized by Toll-like
receptor 5 (TLR5) to trigger cell activation and induce innate immune responses . Cytosolic
flagellin  can also be recognised by the apoptosis-inhibitory protein (Naip5) leading to the
oligomerization of CARD domain-containing protein-4 (NLRC4/Ipaf) followed by caspase-1
activation resulting in IL-1β maturation and release in a TLR5-independent manner  . It has
previously been shown that flagellin acting as a protein type PAMP, contains MHC class-II
epitopes  and is  also  able  to  activate  T-lymphocytes  in  an  antigen  specific  manner.  Thus
flagellin has been identified as a unique and highly efficient activator of adaptive immune
responses . In addition to these properties, flagellin acts as a T-cell dependent antigen and is
able to induce robust B-cell responses to induce simultaneous activation of both arms of the
adaptive immune response.   . Thus, flagellin represents a unique type of protein which can be
recognized by both PRRs and antigen specific receptors; emerging as a protein with adjuvant
properties.  The  bifunctional  character  of  flagellin  also  allows  T-cell  activation  through
different  mechanisms  that  involve:  1)  modification  of  T-cell  functional  activities  when
presented as a TCR epitope ; 2) direct stimulation of PRRs when expressed on the cell surface
of T-lymphocytes ; 3) activation of antigen presenting cells by PRR triggering . 
Mechanistically, apoptosis can be executed by both intrinsic and extrinsic mechanisms. Stress
stimuli act preferentially via permeabilization of the mitochondrial membrane, which triggers
the  intrinsic  activation  pathway  regulated  predominantly  by  the  actual  balance  of  the
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interacting pro- and anti-apoptotic proteins belonging to the Bcl-2 family, as well by the ratio
of proteins involved in the regulation of mitochondrial  depolarization.  In contrast  to these
mechanisms, the extrinsic pathways are mediated by cell death receptors, including the Fas
(CD95/Apo-1/TNFSR6) receptor-ligand system. Engagement of the cell death receptors by
FasL leads to the rapid recruitment of the adapter molecule FADD,  while the pro-enzyme
caspase-8 interacts  through its  death-effector domain (DED)  with the homologous DED of
FADD forming the death-inducing signalling complex (DISC).  These events  result  in  the
activation and processing of caspase-8 acting as an initiator caspase. Depending on the actual
level of activated caspase-8, the executing caspases become activated directly in type-I cells
or require the cleavage of Bid to trigger the mitochondrial apoptotic pathway in type-II cells.
The truncated  form of  Bid  (tBid)  dominates  the  pro-apoptotic  phase  of  the  Bcl-2 family
actions thus turning the balance of the anti- and pro-apoptotic proteins towards mitochondrial
depolarization (Reviewed in ). These apoptotic pathways finally converge to the activation of
effector caspases, preferentially to caspase-3, caspase-6 and caspase-7. 
Death receptors can also induce apoptosis through different molecular pathways:1) aside from
the classical TNF-FADD-caspase-8 complex, a RIP1-dependent cell death route can also be
activated resulting in the formation of ripoptosomes  associated with cell death independently
of mitochondrial depolarization . 2) Depending on the availability of active caspases, RIP1-
mediated cell death may also lead to apoptosis or programmed necrosis i.e. necroptosis. 
It is also well established that these cell death modalities may affect the activation of both
innate and adaptive immunity.  Dying cells in general may initiate innate immune responses
by producing damage associated molecular patterns (DAMPs) referred to as inflammatory cell
death. Dendritic cells (DC) have the potential to continuously engulf dead cells and are able to
present the generated antigenic fragments, derived from the infected or malignant cells, to
trigger naïve cytotoxic T cells, while cross-priming remains the only route to initiate classical
CD8+T cell responses. Ongoing RIP1-mediated cell death signaling in dying cells supports
the efficacy of cross priming and also increases the immunogenicity of DCs. Thus during the
RIP1-dependent pathway the cell death process, also referred to as immunogenic cell death,
has been shown to activate efficient cross-presentation . 
The  contribution  of  flagellin  to  various  cell  death  signaling  events  is  associated  with
considerable ongoing discussion, since both the anti- and the pro-apoptotic characteristics of
flagellin  have  been  described.  For  example,  decreased  apoptosis  has  been  detected  in
epithelial  cells  or  in  neutrophil  granulocytes  upon  treatment  with  purified  flagellin  or
flagellated bacteria, as compared to non-flagellated variants   , and death receptor-mediated
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apoptosis could also be inhibited by flagellin  . In contrast to these results, flagellin was also
found  to  be  able  to  elicit  cell  death  in  different  cell  types  including  primary human
macrophages, IEC6 intestinal epithelial cells and HeLa cells  . Furthermore, the extrinsic cell
death  pathway could  also be initiated  in  a  TLR5 dependent  manner  .  In  the  presence  of
Legionella pneumophilia in Jurkat cells the processing of caspase-3 and caspase-9 could be
observed, but it could not be detected in the presence of a flagellin deficient variant of the
bacteria . 
Here, we demonstrate for the first time that flagellin has the potential to enhance the efficacy
of death receptor-mediated apoptosis in a RIP dependent manner, while it has marginal effects
on the intrinsic  cell  death  process.  Based on these results  we suggest  that  the  regulatory
pathways identified  by the current  study could be harnessed for  vaccination  strategies  by
using flagellin as a potential adjuvant. 
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2. MATERIALS AND METHODS
2.1 Cell lines: The human Jurkat T-cell line, its RIP1-deficient variants and the human WSU
B-cell  line were cultured in  RPMI 1640 medium supplemented  with 10% FCS, 2 mM l-
glutamine, 10 U/ml penicillin, 10 g/ml streptomycin, 10 mM HEPES and maintained at 37ºC
in a humidified atmosphere with 5% CO2. 
2.2  Antibodies  and  reagents:  Ultrapure  recombinant  flagellin  and  neutralizing  anti-TLR5
were purchased from Invitrogen. FasL and the mitochondrium dye DiOC6 were from Enzo
Life Sciences. TNF and IL-2 were purchased from PeproTech, the anti-flag M2 antibody,
RNase  A,  propidium  iodide  (PI),  necrostatin-1  and  paclitaxel   from Sigma-Aldrich.  The
antibodies were purchased from the following companies: Biolegend (APC-labelled anti-Fas
(DX2) and anti-TNFR The luminescent substrate caspase-3 was from Promega, anti-CD11c
for flow cytometry analysis was from Biolegend, the CellTracker was from Lifetech, and Z-
Vad were from Apexbio. 
 
2.3 Flow cytometry:  106  Jurkat  cells  were cell  surface-stained with APC-labelled  anti-Fas
mAb (clone DX2) or anti-TNFR for 30 min on ice. Cells were analyzed by flow cytometer
(FACS Calibur; Becton Dickinson) using the CellQuest software (Becton-Dickinson).
2.4 Production of T cell supernatants: Freshly separated PBMCs were activated with 2 g/ml
PHA for 6 days using 2 ng/ml IL-2 in cell culture medium changed every 48 hours. At a
density  of  4x106 cells/ml  the  cells  were  harvested  on  day  6,  and  the  T-cell  blasts  were
stimulated with 100 g/ml PHA for 5 min. Following cell activation and repeated washings,
the cell cultures were replenished with fresh medium. After 2 hours the supernatants were
collected and the target cells were triggered with the supernatants of PHA activated T-cells
for 24 hours. To get the same cell death intensity, in case of wild type cells T-sup was diluted
(1:2), while remained undiluted when used for RIP1 deficient cells. The degree of cell death
was determined by flow cytometry by detecting the subG1 population. 
2.5 Bacterial supernatants: The culture supernatants derived from wild type and/or flagellin
deficient  FliC-/- Salmonela  enteritidis were  centrifuged  at  15,000  ×  g for  30  min.  The
supernatant  was  dialyzed  against  10  mM  Tris-HCl  buffer  and  the  dialyzed  sample  was
concentrated with a 10k Amicon Ultra device.
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2.6 Cytotoxicity assays: 5x105 cells in a volume of 0,5 ml were pre-treated with 100 ng/ml
recombinant flagellin for 60 min. The sensitivity of the target cells to cell death was examined
by incubating the cells with 20 ng/ml recombinant Flag-tagged FasL, 10 ng/ml recombinant
TNF  or  with  500  ng/ml  paclitaxel.  Alternatively,  cells  were  subjected  to  354  nm  UV
irradiation for 10 min. The degree of cell death was analyzed by measuring caspase-3 activity
detecting  mitochondrial  membrane  depolarization,  Annexin  V  staining,  as  well  as  by
measuring the subG1 peak indicating apoptotic cells.
SubG1 measurement: Cells were fixed on ice-cold 70% ethanol, washed with 38 mM citrate
buffer (pH 7.4) and were incubated in 38 mM citrate buffer supplemented with 50 mg/ml PI
and 5 mg/ml RNase A for 15 min. The treated cells were analyzed by a FACS Calibur flow
cytometer (BD Biosciences) followed by measuring the proportion of subG1 particles. 
Annexin V detection kit (Biovison) was used according to manufacture’s protocol. Caspase-3
activity was measured after the pretreatment of the cells with 100 ng/ml recombinant flagellin
for 1 hour followed by incubation with 60 ng/ml FasL for 24 hours at 37ºC. We used the cell-
permeable fluorogenic substrate Caspase-Glo® 3/7 Promega Assay for monitoring caspase-3
activity in the intact cells, according to the manufacturer’s recommendations. Mitochondrial
depolarization was measured following pre-incubation with 100 ng/ml recombinant flagellin
for 1 hour and stimulation with 20 ng/ml FasL for 4 hours at 37ºC. Thereafter, the cells were
incubated  with  20  nM  DiOC6  for  30  min  at  37ºC.  After  three  washing  steps  in  PBS,
mitochondrial depolarization was detected by a FACS Calibur flow cytometer.
2.7 Co-cultures: The FasL-overexpressing WSU B-cell line used as effector cells were re-
suspended in 5 mM CellTracker. After 30 min incubation at 37ºC the cells were centrifuged,
the CellTracker solution was replaced with fresh medium and cells were incubated for another
30 min at 37°C. After repeated washing steps the cells were added to the target cells at a ratio
of 1:1 or 5:1. Effector and the target cells were co-cultured for 24 hours and the percentage of
dead cells was determined in the CellTracker negative population by flow cytometry. 
2.8 Detection of necroptotic cells: Jurkat cells were pre-treated with 10 μM Z-Vad and 40 μM
necrosatin-1 for 1 hour. As a next step the cells were incubated with flagellin for another hour
and were co-incubated with the effector cells for 24 hours. Following the CellTracker staining
of the FasL-overexpressing WSU B-cells the ratio of the effector and the target cells were
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adjusted to 5:1. Before the flow cytometry analysis the cells were stained with 10 µg/ml PI.
Total cell death was quantified based on the loss of membrane integrity and the uptake of PI.
 
2.9 Statistical analysis: Mean values plus standard deviation of at  least  three independent
experiments are shown.  Statistically significant differences were determined by using one-
way ANOVA test.  *: p < 0.05; **: p < 0.01 and ***: p < 0.001.
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3. RESULTS
3.1 Recombinant flagellin upregulates Fas-induced apoptosis
Flagellin has been identified as a PAMP, which can be presented for T-cells.  Apart from
providing proper  activation  signals  to  the  TCR, flagellin  is  also able  to  initiate  signaling
cascades  in  T cells  mediated  by  PRR activation.  In  this  study we aimed to  identify  and
characterize the functional activities of flagellin in the course of various cell death processes,
with special emphasis on its role in the extrinsic DR-mediated cell death process.    . As a
model  system,  we  designed  in  vitro experiments  using  Jurkat  acute  leukemia  T-cells
expressing TLR5 . The expression of TLR5 on the surface of Jurkat T-cells could be detected
at  both RNA and protein  levels   and functional  assays  confirmed the  operation  of  active
flagellin-mediated  signaling  events  associated  with  NF-κB  activation  ,  cytokine  and
chemokine production  . 
To analyze the effects of flagellin on Fas-induced apoptosis, we first used the FasL sensitive
SVT35 Jurkat T-cells pre-treated with 100 ng/ml recombinant flagellin. In this experimental
setup cell death was induced by flag-tagged recombinant FasL crosslinked with an anti-flag
antibody, or with FasL-expressing WSU B-cells. The degree of cell death was quantified after
24 hours by monitoring the extent of apoptosis given in the percentage of cells containing
sub-diploid  DNA  (subG1)  (supplementary  Figure  1A).  T  cell  death  intensity  was  also
determined with annexin V staining (supplementary Figure 1B). These results indicated that
the treatment of Jurkat T-cells with flagellin only had no modifying effect on apoptosis, but
the  pre-treatment  of  Jurkat  cells  with  flagellin  significantly  increased  the  degree  of  Fas-
induced  apoptosis  (Figure  1A,  B).  Importantly,  the  elevated  level  of  apoptosis  was
independent on the mode of Fas receptor-mediated stimulation, since flagellin could enhance
the cell death process induced by soluble recombinant as well as cell surface expressed FasL.
In contrast, the WSU cells not expressing FasL were unable to induce cell death (data not
shown). In a further step the kinetics of flagellin-mediated Fas-induced cellular killing was
monitored.  Flagellin  were able to increase the Fas-induced cell  death as early as 8 hours,
however significant differences was detected only upon 24 hours (Figure 1C). These results
clearly  demonstrate  that  the  pre-treatment  of  Jurkat  cells  with  recombinant  flagellin  is
sufficient to upregulate the Fas-induced cell death process.
3.2 The culture supernatants of flagellin secreting bacteria can enhance the Fas-induced cell
death process 
9
The observation  that  recombinant  flagellin  is  able  to  promote  the  Fas-induced cell  death
process prompted us to test the effects of flagellin, released by live bacteria. In this context we
addressed the question of whether the supernatants derived from the  Salmonella enteritidis
strain  and  its  flagellin  deficient  counterpart  could  modulate  the  Fas-induced  cell  death
process. In this experimental setting Jurkat cells  were pre-treated with filtered cell  culture
supernatants containing >10 kDa molecules released from bacteria, which expressed or lacked
flagellin. In this experimental setting the flagellin free supernatants had no effect on the Fas-
mediated cell death process, while the supernatants of wild type flagellin expressing bacteria,
similarly  to  the  recombinant  flagellin,  were  able  to  increase  the  intensity  of  Fas-induced
apoptosis   (Figure 2). Considering that the supernatants of flagellin deficient bacteria did not
modify the outcome of the Fas-induced cell  death process, these experiments point to the
contribution of flagellin to the regulation of Fas-mediated apoptosis. Overall,  these results
confirm that in Jurkat T-cells flagellin mediates a supportive effect on the Fas-induced cell
death process. 
3.3 Recombinant flagellin has the potential to increase the level of death receptor-induced
apoptosis in a TLR5 dependent way.
Confirming that flagellin has the potential to enhance the activity of Fas-induced cell death,
we  sought  to  analyze  the  impact  of  flagellin  on  other  types  of  death  receptor-mediated
signaling events. Taken that the SVT35 Jurkat cells are sensitive to TNF-induced apoptosis,
we aimed to determine the contribution of flagellin to the TNF-induced signaling pathways.
To this end, the cells were first pre-treated with 100 ng/ml recombinant flagellin for an hour
followed by the stimulation of the cells with 10 ng/ml recombinant TNF for 24 hours. Similar
to  the  results  obtained  during  the  Fas-generated  cell  death  process,  flagellin  could
significantly enhance TNF-induced apoptosis (Figure 3A). 
Killing of target cells by cytotoxic T-lymphocytes is induced by direct cell-to-cell  contact
and/or by secreted microvesicles . FasL, TRAIL , TNF  and other soluble factors  may also
contribute to the cytotoxic activities of these T-cell supernatants.  Considering the possible
involvement of other contributing factors and mechanisms exerted on the various cell death
processes, we also measured the killing potential of the T-cell supernatants (T-sup) both in the
presence and absence of flagellin. In accordance with our previous results we found that the
supernatants derived from PHA-activated primary T-cells exhibited cytotoxic activity, which
culminated  in  the killing  of  Jurkat  cells   .  These experiments  revealed  that  flagellin  pre-
treatment was able to enhance the degree of the activated T-lymphocytes derived supernatant-
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induced cell death,  similarly to the results obtained from recombinant  FasL or TNF (Figure
3B). These results confirmed the significant contribution of flagellin to the upregulation of the
cell death process induced by cytotoxic T-cells upon soluble factor-mediated stimuli.
To test whether flagellin-mediated enhancement of death receptor-induced cell death was a
TLR5 dependent process, we pretreated the cells with a neutralizing anti-TLR5 antibody for 1
hour. Antagonistic TLR5 antibody completely blocked the flagellin-induced enhancement of
death receptor triggered apoptosis (Figure 3C) suggesting that flaggelin exerts its effect on
cell death by the means of TLR5 signaling.
3.4 Flagellin has no modulatory effect on the cell death process in neutrophil granulocytes 
As shown before , flagellin is able to inhibit apoptosis in neutrophil granulocytes when an
agonistic  anti-Fas  antibody  was  used.  To  get  a  better  insight  into  the  cell  death  process
initiated in neutrophil granulocytes, fresh neutrophil granulocytes were treated with flagellin
in the presence or absence of recombinant FasL. Subsequently, the intensity of cell death was
determined by capturing the subG1 cell population 8 hours after FasL-mediated stimulation.
As expected, granulocytes readily undergo spontaneous cell death at as early as 8 hours, and
this process could be further increased by FasL-mediated stimulation. However, flagellin pre-
treatment  was  unable  to  elevate  the  cell  death  process  both  in  non-stimulated  or  FasL
activated cells at any of the investigated time points suggesting that the flagellin-mediated
enhancement of death receptor-induced cell death is strictly cell type dependent (Figure 4). 
3.5  Flagellin  pre-treatment  upregulates  caspase-3  activation,  but  it  has  no  effect  on
mitochondrial depolarization 
In  the  course  of  cell  death  receptor  mediated  signaling  the  possible  molecular  targets  of
flagellin have not yet been identified.  To get insight into the multi-stage processes of cell
death  events  we  next  sought  to  identify  the  checkpoints  of  the  cell  death  events  in  the
presence of flagellin. First, we measured the expression level of Fas and TNF receptors on the
cell surface followed by flagellin treatment. The histograms presented in Figure 5A and B
demonstrate that the level of TNF receptor expression remains unaffected for 24 hours, but
Fas expression was increased upon flagellin-induced stimulation. Thus the supportive effect
of flagellin during the cell death process can partially attributed to the up-regulated expression
of the Fas receptor, but it cannot explain the flagellin-mediated upregulation of TNF-induced
cell death.
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Death receptor-mediated  stimulation  can also induce  caspase-3 activation  with or without
mitochondrial  depolarization  depending  on the  action  of  type  I  or  II  cells.  Flagellin  pre-
treatment did not change the intensity of mitochondrial membrane depolarization caused by
FasL stimulation (Figure 5C). In contrast to these observations, co-stimulation with FasL and
flagellin  provoked enhanced  caspases-3  activity  at  both  6  and 24 hours  after  stimulation
(Figure 5D). This is consistent with the increased apoptotic cell death detected in the subG1
cell population. Identification of these molecular actors of the Fas/TNF signaling pathway led
us to conclude that flagellin has no direct impact on mitochondrial depolarization, but it is
involved in downstream processes including effector caspase activities, which may contribute
to the flagellin-mediated enhancement of cell death. 
3.6 Flagellin is inefficient to modulate stress induced apoptosis
Apoptosis can be mediated by both intrinsic and extrinsic processes. Taken that flagellin can
modify  the  activity  of  effector  caspases  without  affecting  mitochondrial  membrane
depolarization, we sought to study the potential role of flagellin in stress-induced apoptosis.
To this end we incubated the SVT35 Jurkat cells with flagellin for 1 hour followed by UV
irradiation, or treatment with the chemotherapeutic agent paclitaxel to provoke mitochondrial
apoptosis. In contrast to the results obtained with death receptor-induced apoptosis, flagellin
pre-treatment was unable to enhance stress-induced apoptosis. This suggests that even though
flagellin  has the potential  to regulate  death receptor-mediated apoptosis,  it  does not affect
mitochondrial depolarization (Figure 6).
3.7 Flagellin enhances the cell death process in a RIP1-dependent manner 
As outlined  in  the previous  sections,  flagellin  is  able  to  increase  death receptor-mediated
apoptosis,  but  has  no  effect  on  mitochondrial  membrane  depolarization  or  on  the  stress-
induced pathway. Based on this data, we investigated the possible action of a putative death
receptor-dependent but mitochondria independent process, which might be responsible for the
facilitation of cell death induction. Considering that the RIP1-dependent pathway has been
identified upon death receptor stimulation and can induce caspase-9 independent apoptosis ,
we  sought  to  investigate  whether  RIP1  could  be  essential  for  the  flagellin-induced
enhancement of the Fas-mediated cell death process. To approach this scenario, SVT35 Jurkat
cells  and their  RIP1-negative  sub-clones  were  pre-treated  with  flagellin  and subsequently
stimulated with FasL, TNF, or T-sup. RIP1 deficiency of the sub-clones was confirmed by
western blotting , and both the wild type and its RIP1-negative counterparts were sensitive to
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FasL-induced cell death. Nevertheless, flagellin pre-treatment resulted in significantly more
intense cell  death in  the wild type cells  compared to  the RIP1 deficient  cells  upon FasL
stimulation (Figure 7A). To further confirm the impact of flagellin on other types of death
receptor-mediated signaling events, after flagellin pre-treatment, we activated the cells with
TNF or T-sup. In accordance with our published results , T-sup could induce RIP1 dependent
cell  death .  These results  showed that,  in contrast  to the wild type cells, flagellin  did not
increase the intensity of T-sup- and TNF-induced cell death in the RIP1 deficient cell lines
(Figure 7 B, C). These results demonstrate that RIP1-mediated signals are responsible at least
partially for flagellin-mediated upregulation of FasL, TNF and Tsup -induced apoptosis.
DR-mediated stimulation of cells may also result in other types of RIP1-regulated cell death
processes such as programmed necrosis or necroptosis. Necroptosis utilizes a unique signaling
pathway, which aside from RIP1, also requires the involvement of  RIP3  and MLKL  . Upon
stimulation  of  DRs,  necroptosis  requires  inhibited  caspase  activities   or  the  lack  of  the
caspase-8-activating adaptor FADD , demonstrating the crucial role of the apoptotic platform
in  the  regulation  of  necroptosis. To  determine  whether  flagellin  affects  DR-stimulated
necroptosis or its effect is restricted exclusively to DR-mediated apoptosis, we treated the
SVT35 Jurkat cells with flagellin and with FasL simultaneously in the presence of the pan-
caspase inhibitor  Z-Vad. We found that  in the presence of Z-Vad strong stimulation was
essential to provoke cell death. This indicates that necroptosis could only be induced by the
FasL-expressing WSU B-cells  used at  elevated  (5:1) effector/target  cell  ratios.  Strikingly,
flagellin  pre-treatment  of  Jurkat  cells  was able  to  increase  Fas-induced  necroptosis  to  an
extent similar to that observed in apoptotic conditions. 
Necroptosis  can be specifically  inhibited  by necrostatins  (Nec1)   or  by neurosulfonamide
NSA . Accordingly, in the presence of Z-Vad, the cell death process could be completely
blocked by necrostatins confirming that the observed cell death processes can be validated as
necroptosis. These results altogether demonstrate that flagellin pre-treatment supports both the
RIP1 dependent apoptotic and necroptotic pathways.
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4. DISCUSSION
Activation of naïve cytotoxic T cells requires the engulfment of dying cells by DCs and the
cross-presentation  of  cellular  antigens.  Optimized  adjuvants,  relevant  to  intracellular
pathogens or tumor antigens, are not only able to activate innate immune responses, but they
also preferentially induce immunogenic cell death. Agonists, which are able to activate TLRs,
have been tested to boost immune responses to enforce increased anti-tumor activities . As an
example, the stimulation of TLR3 or TLR4 are well known inducers of  DC maturation and
concomitantly induce cell death to facilitate antigen cross-presentation by DC .  Flagellin is
considered as an unique pathogen-derived protein,  which is  recognized by innate  immune
cells  and  also  by  various  adaptive  immune  receptors  simultaneously,  thus  providing  an
important link between the two arms of the immune system. The effects of flagellin on innate
immune cells, and its ability to activate T-cells  directly identifies flagellin as an adjuvant
acting  against  infectious  diseases  and/or  supporting  the  outcome  of  anti-cancer
immunotherapies .  Several approaches and various targeting strategies have already utilized
flagellin operating as an adjuvant in cancer immunotherapy. Co-administration of flagellin
with tumor antigens has also been tested and revealed its capacity to facilitate the induction of
anti-tumor immunity    .
In  this  study we have  undertaken a  detailed  characterization  of  flagellin-mediated  effects
exerted on various cell death pathways. We demonstrated that the pre-treatment of Jurkat T
cells  with recombinant  flagellin  was able  to  increase  the  level  of  Fas-mediated  apoptosis
significantly. We also provided evidence that this type of cell death was independent of the
mode of death receptor triggering,  since the signals induced by both recombinant and cell
surface expressed FasL were equally effective. Importantly, in the presence of flagellin the
TNF- killing mechanisms could also be enhanced. 
It has previously been reported that the cytotoxic function of T-cells acts as a Fas-dependent
mechanism in concert with other death receptors. Soluble FasL, TNF and TRAIL have also
been observed in the culture supernatants of activated T-lymphocytes suggesting that, aside
from direct cell-to-cell contact-induced killing mechanisms, secreted vesicles are also able to
transfer cytotoxic signals to various target cells . 
In the current  in vitro model system we sought to investigate the impact of soluble factors,
such  as  culture  supernatants  derived  from PHA pre-stimulated  T-cells.  The  experimental
results provided evidence that aside from the death ligand-induced cell death process, T-sup-
mediated apoptosis can also be sensitized by flagellin. Upregulation of activation-induced cell
death (AICD) has been evaluated as an immune evasion strategy, which decreases the number
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of  antigen-specific  T  cells.  At  the  same  time,  this  process  can  also  contribute  to  the
maintenance  of  immune  tolerance,  especially  in  the  vicinity  of  mucosal  surfaces  where
significant amounts of flagellin is constantly available. The modulatory effects of flagellin via
the down-regulation of the lifespan of activated T-cells points out the requirement of further
studies related to the in vivo application of flagellin as an adjuvant. 
It is reasonable to assume that bacterial supernatants may contain a wide range of biologically
active components, including flagellin monomers. To determine the significance of flagellin
mediated effects, the characteristics of flagellin deficient and wild type Salmonella enteritidis
bacteria  were  compared  based  on  their  ability  to  induce  apoptosis.  In  this  experimental
setting,  the  supernatants  derived from flagellin  expressing  bacterium strains  were able  to
increase the FasL-induced cell  death process, while the flagellin deficient supernatant was
ineffective, confirming the apoptosis enhancing potential of flagellated bacteria. This result
also highlights the unique role of flagellin present in bacterial supernatants and the ability to
modulate the Fas-mediated cell death process. 
Our results demonstrate that although flagellin has an impact on the outcome of Fas-induced
cell  death  and  on  the  activation  of  downstream  effector  caspases,  the  intensity  of
mitochondrial depolarization remained unaffected. 
Following  TNF  or  FasL  stimulation,  RIP1-dependent  apoptosis  and  also  necroptosis  are
induced.  Depending  on  the  posttranslational  modifications,  the  proteolytic  inactivation  of
RIP1 and RIP3, as well as the poly-ubiquitinated status of RIP1, in line with the composition
of the organized molecular complexes, RIP1 is able to modulate the final outcome of cell
death mediated signaling events . RIP1 signaling in dying cells has been found to facilitate
cross-presentation in cytotoxic T cells , . Our results also demonstrate that in the absence of
RIP1  flagellin  is  unable  to  enhance  the  death  receptor  and  the  T-sup-induced  apoptosis
processes.  It  indicates  that  flagellin  can  upregulate  the  RIP1-mediated  cell  death  process.
Since caspase activation was not inhibited in these settings, RIP-mediated apoptosis could  be
induced. 
However, in the presence of the caspase inhibitor Z-Vad intense FasL triggering can induce
RIP-dependent  necroptosis  in  Jurkat  cells.  Similarly  to  Fas-induced  apoptosis,  RIP-1
dependent necrosis was also enhanced by flagellin pre-treatment. 
The  immunological  nature  of  the  various  cell  death  processes  can  either  be  tolerogenic,
inflammatory or immunogenic.  Thus, the  various cell death processes have the potential to
fundamentally  impact  the  development  of  degenerative  disorders,  autoimmune  processes,
inflammatory diseases and tumors. The results obtained in this study indicate that flagellin not
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only activates DCs by acting as a PAMP, but at the same time may also direct various cell
death pathways towards the RIP-dependent cell death pathway, which may result in enhanced
DC-mediated cross-presentation. This unique capability of flagellin designates it as a potent
adjuvant, which can be readily harnessed  for different therapeutic settings, preferentially in
tumor immunotherapies. 
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FIGURE LEGENDS
Figure 1. Flagellin pre-treatment enhances the activity of Fas-induced cell death
Cells of the SVT35 Jurkat T-cell line were pre-treated with 100 ng/ml recombinant flagellin
for 1 hour followed by (A)  the activation of cells with flag-tagged recombinant FasL (20 ng/
ml) crosslinked with the anti-flag (M2) antibody, or by (B) co-culturing with the human B-
cell line WSU expressing FasL at a ratio of 1:1.  After 24 hours the extent of cell death was
determined by measuring the subG1 peak.  Figure A and B show the mean plus standard
deviation (SD) of at least four independent experiments. (C) Jurkat T-cells were pre-treated
with  100 ng/ml  flagellin  followed  by  the  activation  with  20  ng/ml  recombinant  FasL in
combination with the M2 anti-flag antibody. After the indicated period of time the level of
cell death was determined by measuring the subG1 peak. A representative image of three
independent experiments is shown. 
Figure 2. Flagellin expressing, but not the flagellin deficient, bacterial supernatants are able
to increase the degree of Fas-induced cell death
The  supernatant  of  Salmonella  enteritidis bacterial  cultures  was  dialyzed  and  the  low
molecular weight fraction (< 3kD) was removed by ultrafiltration. Jurkat T-cells were treated
with the filtered supernatants of wt (FliC) or flagellin deficient bacteria (FliC-/-) for 1 hour.
The pre-treated cells were stimulated with 20 ng/ml recombinant FasL in combination with
the  M2  anti-flag  antibody.  After  24  hours  the  degree  of  cell  death  was  determined  by
measuring  the  subG1 peak.  Figure  shows the  mean  plus  standard  deviation  (SD) of  five
independent experiments.
Figure 3. Flagellin pre-treatment enhances the death receptor-induced cell death process
(A) Jurkat T-cells were pre-treated with 100 ng/ml flagellin for 1 hour followed by activation
with 10 ng/ml recombinant TNF. After 24 hours the level of cell death was determined by
measuring the subG1 peak. (B) Following the pre-incubation of the Jurkat cells  with 100
ng/ml flagellin, the cells were treated with the supernatants of PHA-activated 6 days T cell
blasts (T-sup). After 24 hours the level of cell death was determined by measuring the subG1
peak. (C) Jurkat T-cells were pre-treated with 100 ng/ml flagellin for 1 hour in the presence or
absence of neutralizing anti-TLR5. Cells were activated with flag-tagged recombinant FasL
(20 ng/ml) crosslinked with the anti-flag (M2) antibody, 10 ng/ml recombinant TNF or with
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the supernatants of PHA-activated 6 days T cell blasts (T-sup). After 24 hours the intensity of
cell death was determined by measuring the subG1 peak. Figure (A-C) show the mean plus
standard deviation (SD) of at least five independent experiments.
Figure 4.  Flagellin pretreatment has no effect on the spontaneous or the Fas-induced cell
death process in neutrophil granulocytes
Freshly isolated neutrophil granulocytes were treated with 100 ng/ml recombinant flagellin.
Alternatively,  the  cells  treated  with flagellin  for  1  hour  were  also activated  by 20 ng/ml
recombinant FasL for 8 hours and the degree of cell death was determined by measuring the
subG1 peak. The figure shows the mean plus SD of three independent experiments. 
Figure 5. Flagellin pre-treatment upregulates caspase-3 activation 
Jurkat cells were pretreated with 100 ng/ml recombinant flagellin for 24 hours. (A) Fas and
(B) TNF receptor expression levels were detected by fluorescently labelled anti-Fas or anti-
TNFR antibody. A representative image of three independent experiments is documented. (C-
D) Jurkat cells were pre-treated with 100 ng/ml flagellin for 1 hour followed by activation
with 20 ng/ml recombinant FasL together with the anti-flag M2 antibody. (C) 4 hours after the
addition of FasL mitochondrial depolarization was determined by using the DIOC6 dye. (D)
24 hours after the addition of FasL to the Jurkat cells, caspase-3 activity was determined by
measuring luminescent intensity. 
Figure 6. Flagellin pre-treatment has no effect on intrinsic apoptosis 
Cells of the Jurkat cell line were pre-treated with 100 ng/ml flagellin for 1 hour and stimulated
by (A) 354 nm UV irradiation for 10 minutes or (B) paclitaxel (500 ng/ml) treatment. After 24
hours the degree of cell death was determined by measuring the subG1 peak. Figures show
the mean plus SD of three independent experiments. 
Figure  7.  Flagellin  pre-treatment  increases  the  cell  death  process  in  a  RIP1-dependent
manner
(A-C) RIP1 deficient SVT35 Jurkat cells and their wild type counterpart were pre-treated with
100 ng/ml flagellin for 1 hour followed by activation (A) with 20 ng/ml FasL crosslinked with
the anti-flag (M2) antibody, (B) with 10 ng/ml recombinant TNF, or (C) with the supernatants
of PHA-activated T cells (T-sup). In case of wild type cells T-sup was diluted (1:2), while
remained undiluted for the RIP1 deficient cells. After 24 hours the degree of cell death was
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determined  by  measuring  the  subG1  peak.  Figures  show  the  mean  plus  SD  of  five
independent experiments  and significance was determined by using the two-way ANOVA
test. (D) Cells of the Jurkat cell line were incubated in the presence or absence of 10 μM Z-
Vad and 40 μM necrosatin-1 for 1 hour. After 1 hour pre-treatment with flagellin the FasL-
overexpressing WSU B-cell line was added to the Jurkat cells at a 5:1 ratio. The degree of
total cell death was quantified based on the uptake of PI. Figure shows the mean plus SD of
four independent experiments and significance was determined by using paired t-test.
Supplementary Figure1.
(A) Cells of the SVT35 Jurkat T-cell line were pre-treated with 100 ng/ml recombinant
flagellin for 1 hour followed by the activation of cells with flag-tagged recombinant FasL (20
ng/ml) crosslinked with the anti-flag (M2) antibody. After 24 hours the extent of cell death
was determined by measuring the subG1 peak. A representative image of five independent
experiments is documented.
(B) Jurkat  T-cells  were  pre-treated  with  100  ng/ml  flagellin  for  1  hour  followed  by
activation with 10 ng/ml recombinant FasL in the presence of anti-flag (M2) antibody. In 8
hours  the  level  of  cell  death  was  determined  by  Annexin  V  and  7AAD  staining.  A
representative image of three independent experiments is documented.
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